bioRxiv Science⌕ Search

Biology subjects

Spyrou, J.

Publications and source records attributed to Spyrou, J..

2 recordsLinked to original sources
bioRxiv2024

Slc35a2 mosaic knockout impacts cortical development, dendritic arborisation, and neuronal firing in the developing brain

ObjectiveMild malformation of cortical development with oligodendroglial hyperplasia in epilepsy (MOGHE) is an important cause of drug-resistant epilepsy. A significant subset of individuals diagnosed with MOGHE display somatic mosaicism for loss-of-function variants in SLC35A2, which encodes the UDP-galactose transporter. We developed a mouse model to investigate the mechanism by which disruption of this transporter leads to a malformation of cortical development. MethodsWe used in utero electroporation and CRISPR/Cas9 to knockout Slc35a2 in a subset of layer 2/3 cortical neuronal progenitors in the developing brains of fetal mice to model mosaic expression. ResultsHistology of brain tissue in the mosaic Slc35a2 knockout mice revealed the presence of upper layer-derived cortical neurons in the white matter. In contrast, oligodendrocyte patterning was unchanged. Reconstruction of single filled neurons identified altered dendritic arborisation with Slc35a2 knockout neurons having increased complexity. Whole-cell electrophysiological recordings revealed that Slc35a2 knockout neurons display reduced action potential firing and increased afterhyperpolarisation duration compared with control neurons. Mosaic Slc35a2 knockout mice also exhibited significantly increased epileptiform spiking and increased locomotion. InterpretationWe successfully generated a mouse model of mosaic Slc35a2 deficiency, which recapitulates features of the human phenotype, including impaired neuronal migration. We show that knockout in layer 2/3 cortical neuron progenitors is sufficient to disrupt neuronal excitability and increase epileptiform activity and hyperactivity in mosaic mice. Our mouse model provides a unique opportunity to investigate the disease mechanism(s) that underpin MOGHE and facilitate the development of precision therapies.

neuroscience↗
bioRxiv2024

A precision medicine approach for HCN1 Developmental and Epileptic Encephalopathy

Pathogenic variants in HCN1 causing cation leak result in a severe developmental and epileptic encephalopathy (DEE). Current treatment options for patients with HCN1-DEE are limited and are insufficient to fully address both the seizures and clinical comorbidities of this disorder. Org 34167 is a brain penetrant broad-spectrum HCN channel inhibitor that has completed phase I clinical trials. We used a range of assays at molecular, cellular, network and behavioural levels to explore the potential of Org 34167 as a precision medicine for HCN1-DEE. Org 34167 restored the voltage sensitivity of the DEE HCN1M305L mutated channel, significantly reducing cation leak. It also restored Ih-mediated sag, hyperpolarised the resting membrane potential and reduced firing of layer V neurons from the Hcn1M294L mouse model of HCN1-DEE, which was engineered based on the HCN1M305L pathogenic variant. Additionally, Org 34167 reduced neuronal epileptiform activity and restored retinal light sensitivity in these mice, suggesting it may improve both seizures and other clinical comorbidities. However, Org 34167-mediated tremors were noted at therapeutic doses. Org 34167 was also effective at reducing cation leak caused by five additional HCN1 pathogenic variants, suggesting broader utility. Overall, these data demonstrate that a small molecule HCN inhibitor can restore channel and consequent physiological functions, positioning it as a promising precision therapeutic approach for HCN1-DEE.

neuroscience↗